Patent Expiry

Patent/Exclusivity Expiry: OJEMDA

Drug
OJEMDA

Other upcoming events for DAWN

Phase 3 ReadoutPhase 3 Topline: LOGGIC/FIREFLY-2: A Phase 3, Randomized, International Multicenter Trial of DAY101 Monotherapy Versu

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Patent/Exclusivity Expiry: OJEMDA — DAWN Patent Expiry | BioSniper